ClinicalTrials.gg
RecruitingNCT06504368Updated Nov 6, 2025

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

A Phase 1 interventional study of DCR-PDL1 in Solid Tumors, Adult, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (part of Novo Nordisk A/S) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

02

Conditions studied

  • Solid Tumors, Adult
03

In context

Lead sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company is the lead sponsor of 18 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

First submitted after Dicerna Pharmaceuticals, Inc. became part of Novo Nordisk A/S.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults, aged greater than or equal to (≥) 18 years.
  • Participants are required to have a documented, locally advanced or solid tumor , or non-Hodgkin's lymphoma

    • that is to standard therapy known to provide clinical benefit for their condition OR
    • have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR
    • have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR
    • for which no standard therapy is available
  • according to version 1.1.
  • Malignancy not currently amenable to surgical intervention.
  • performance status of 0, 1, or 2, and an anticipated of ≥ 3 months at the time of signing the .
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with known CNS or not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    DCR-PDL1

    Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.

    Drug: DCR-PDL1

Interventions

  • DrugDCR-PDL1

    Solution for IV Infusion

06

What researchers measure

Primary outcomes

  1. Incidence and Nature of Adverse Events (AEs)

    Time frame: Baseline to week 8

  2. Incidence of Dose-limiting Toxicities (DLTs)

    Time frame: Baseline to week 8

  3. Change From Baseline in Vital Signs: Oral, Tympanic, Temporal Artery Temperature

    Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.

    Time frame: Baseline up to week 8

  4. Change From Baseline in Vital Signs: Systolic and Diastolic Blood Pressure

    Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.

    Time frame: Baseline up to week 8

  5. Change From Baseline in Vital Signs: Pulse and Respiratory Rate

    Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position. Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Baseline up to week 8

  6. Change from Baseline in 12-lead Electrocardiogram (ECG): Heart Rate and Pulse Rate

    Time frame: Baseline to week 8

  7. Change from Baseline in 12-lead Electrocardiogram (ECG): QRS intervals

    ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Baseline to week 8

  8. Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervals

    ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Baseline to week 8

  9. Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula)

    ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.

    Time frame: Baseline to week 8

  10. Change from Baseline in Hematology Parameter: Red blood cells, White blood cells, Lymphocytes, Monocytes, Eosinophils, Neutrophils, Basophils and Platelets, Reticulocytes

    Time frame: Baseline to week 8

  11. Change from Baseline in Hematology Parameter: Mean corpuscular volume (MCV)

    Time frame: Baseline to week 8

  12. Change from Baseline in Hematology Parameter: Mean corpuscular hemoglobin (MCH)

    Time frame: Baseline to week 8

  13. Change from Baseline in Hematology Parameter: Hemoglobin

    Time frame: Baseline to week 8

  14. Change from Baseline in Hematology Parameter: Hematocrit and Mean corpuscular hemoglobin concentration (MCHC)

    Time frame: Baseline to week 8

  15. Change from Baseline in Coagulation Parameter: International normalized ratio (INR)

    Time frame: Baseline to week 8

  16. Change from Baseline in Coagulation Parameter: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT)

    Time frame: Baseline to week 8

  17. Change from Baseline in Coagulation Parameter: Fibrinogen

    Time frame: Baseline to week 8

  18. Change from Baseline in Clinical Chemistry Parameter: Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) and Creatine kinase (CK)

    Time frame: Baseline to week 8

  19. Change from Baseline in Clinical Chemistry Parameter: Total protein and Albumin

    Time frame: Baseline to week 8

  20. Change from Baseline in Clinical Chemistry Parameter: Total bilirubin, Direct bilirubin, Fasting blood glucose, Creatinine and Blood urea nitrogen (BUN)

    Time frame: Baseline to week 8

  21. Change from Baseline in Clinical Chemistry Parameter: Sodium, Chloride and Potassium

    Time frame: Baseline to week 8

  22. Change from Baseline in Urinalysis Parameter: Glucose, Protein, Bilirubin and Urobilinogen

    Time frame: Baseline to week 8

  23. Change from Baseline in Urinalysis Parameter: Specific Gravity

    Time frame: Baseline to week 8

  24. Change from Baseline in Urinalysis Parameter: Potential of Hydrogen (pH) of Urine

    Time frame: Baseline to week 8

  25. Change from Baseline in Urinalysis Parameter: Blood

    Time frame: Baseline to week 8

  26. Change from Baseline in Urinalysis Parameter: Ketones and Nitrite

    Time frame: Baseline to week 8

  27. Change from Baseline in Urinalysis Parameter: Leukocyte esterase

    Time frame: Baseline to week 8

  28. Number of Participants with Change from Baseline in Physical Examination Findings: Cardiovascular, Respiratory, Gastrointestinal, and Neurological systems

    A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Pharmacokinetic Plasma Concentrations of DCR-PDL1

    Time frame: Pre-dose up to 48 hours post-dose

  2. Pharmacokinetic Urine Concentrations of DCR-PDL1

    Time frame: Up to 8 hours post-dose

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jul 16, 2024
StartActual
May 29, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06504368
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
May 29, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 6, 2025

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion